Novel psychedelic-based drugs biotech Mydecine Innovations Group, Inc. (NEO:MYCO) (AQSE: MYIG) (OTC:MYCOF) (FSE: 0NFA) completed its admission to Access segment of the UK's stock market, AQSE Growth Market. Trading started on Tuesday under ticker MYIG.
"We are incredibly excited to list our securities for trading in the UK on the AQSE Growth Market," Josh Bartch, CEO of the company stated." We believe Mydecine is at a pivotal phase in its development and look forward to increased exposure to UK and European investors alike."
Mydecine is classified as a Healthcare company on the Access Segment of the Aquis Stock Exchange. It will have a dual listing with its common shares fully fungible through a CREST Depositary Interest (CDI). The CDIs will carry the same ISIN as the Common Shares listed in Canada on NEO. The issued share capital of Mydecine comprises 45.21 million common shares.
Mydecine Highlights
- Mydecine's various families of Novel 2nd generation molecules are showing significant improvements over the first generation of psychedelic treatments.
- The company is currently working with its pre-clinical team at the University of Alberta to work these molecules through the Investigational New Drug enabling stage with the intent to put them into human clinical studies expected to commence in 2024.
- Mydecine has an intellectual property strategy covering novel molecules, drug formulations, delivery mechanisms, and methods of production. It believes this covers all described drug development activities in its named pipeline and clinical trials. The company has filed these applications both in the United States and through the Patent Cooperation Treaty (PCT) for protection in all jurisdictions in which the company does business.
Price Action
Mydecine shares closed Wednesday market session 28.19% higher at 0.12 cents per share.
Related Links:
Mydecine Releases Q2 2023: Developer Of Smoke Cessation Psilocybin Prodrugs & MDMA Analogs
Jamaica Launches Organic Psilocybin Gummies & New Psychedelic Retreat: Rose Hill's New Offer
Mydecine's Prospectus Supplement Closing Under Share Subscription And Management Update
Photo: Courtesy of Mathew Schwartz via Unsplash